VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes

The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities

Lupin receives European Commission approval for biosimilar Ranibizumab

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization

FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer

The NDA filing is supported by results from the phase III evERA Breast Cancer study

BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences

40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions

Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery

GSK’s Exdensur wins EU nod for severe asthma

The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen

Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI

Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care

ExCellThera’s Zemcelpro scores big in Germany, paving way for early hospital access

The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission